Additional indications of Factive probable
Published: 2003-04-09 06:59:00
Updated: 2003-04-09 06:59:00
LG Life Sciences' Factive has received an approval letter from the US FDA as treatment against community-acquired pneumonia and acute exacerbation of chronic bronchitis, and penicillin-resistant S.pneumoniae (PRSP), excluding multi-drug resistant S.pneumoniae (MRSP).
As FDA approved the PRSP ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
